|
Active substance |
Atrasentan |
|
Holder |
Novartis Pharma N.V. |
|
Status |
Running |
|
Indication |
Atrasentan is indicated for the treatment of adults with primary IgA nephropathy at risk of disease progression, with a urine protein excretion ≥1g/day and < 3.5g/day. |
|
Public documents |
|
|
Last update |
25/06/2026 |
Atrasentan
Last updated on